Boston Scientific (NYSE:BSX) Jumps 4.5% This Week, Though Earnings Growth Is Still Tracking Behind Three-year Shareholder Returns
Boston Scientific (NYSE:BSX) Jumps 4.5% This Week, Though Earnings Growth Is Still Tracking Behind Three-year Shareholder Returns
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in a really great company, you can more than double your money. For example, the Boston Scientific Corporation (NYSE:BSX) share price has soared 125% in the last three years. Most would be happy with that. It's also good to see the share price up 16% over the last quarter. But this move may well have been assisted by the reasonably buoyant market (up 6.7% in 90 days).
在购买一家公司的股票后,如果你失去投入的所有资金,那将是最糟糕的结果(假设没有杠杆)。但如果你购买了一家真正优秀公司的股票,你可以获得超过两倍的收益。例如,波士顿科学公司(纽交所:BSX)的股价在过去三年中飙升了125%。大多数人对此会感到满意。 看到过去一个季度股价上涨了16%也很好。 但这一变化可能得益于相对活跃的市场(在90天内上涨了6.7%)。
Since the stock has added US$5.8b to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.
由于该股票在过去一周内增加了58亿美元的市值,我们来看看基本表现是否推动了长期回报。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
虽然有效市场假说仍然被一些人教授,但被证明市场是过度反应的动态系统,投资者并不总是理性的。检查市场情绪如何随时间变化的一种方法是看一个公司的股价与其每股收益(EPS)之间的交互作用。
Boston Scientific was able to grow its EPS at 16% per year over three years, sending the share price higher. In comparison, the 31% per year gain in the share price outpaces the EPS growth. This indicates that the market is feeling more optimistic on the stock, after the last few years of progress. It is quite common to see investors become enamoured with a business, after a few years of solid progress. This favorable sentiment is reflected in its (fairly optimistic) P/E ratio of 75.21.
波士顿科学在三年内年均增长每股收益16%,推动了股价上涨。相比之下,股价年均增长31%超出了每股收益的增长。这表明,经过过去几年的进展,市场对该股票的乐观情绪正在增强。投资者在几年的稳步进展后,常常对某个业务产生兴趣。这种良好的情绪反映在其(相当乐观的)市盈率75.21上。
The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).
下图显示了EPS随时间变化的情况(点击图像以显示确切值)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20241123/0-e6c76ff6b4d0a55db5c145f8f09cec84-0-23479ae0b365067519e957067d949669.png/big)
We know that Boston Scientific has improved its bottom line lately, but is it going to grow revenue? You could check out this free report showing analyst revenue forecasts.
我们知道波士顿科学最近改善了其盈利,但它会增长营业收入吗?你可以查看这份免费的报告,了解分析师的营业收入预测。
A Different Perspective
另一种看法
It's good to see that Boston Scientific has rewarded shareholders with a total shareholder return of 65% in the last twelve months. That's better than the annualised return of 16% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. Before deciding if you like the current share price, check how Boston Scientific scores on these 3 valuation metrics.
很高兴看到波士顿科学在过去十二个月中为股东带来了65%的总股东回报。这比过去五年的年化回报率16%要好,这表明公司最近表现更佳。鉴于股价势头仍然强劲,可能值得更仔细地关注这只股票,以免错过机会。在决定是否喜欢当前股价之前,请查看波士顿科学在这三个估值指标上的得分。
We will like Boston Scientific better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.
如果我们看到一些大型内部人士买入,我们会更喜欢波士顿科学。在我们等待的同时,查看这份免费列表,其中包含一些被低估的股票(大多是小盘股),以及相当可观的最近内部人士买入。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。